Authors of a double-blind, randomised trial suggest that faecal microbiota transplantation could be a promising treatment for patients with ulcerative colitis


According to the results of a study published in The Lancet Gastroenterology & Hepatology, patients with active ulcerative colitis may benefit from treatment with antibiotics followed by orally administered faecal microbiota transplantation (FMT).

The randomised clinical trial included 35 patients. Following 2 weeks of amoxicillin, metronidazole, and doxycycline, 15 patients were randomly assigned to receive FMT and the 20 received placebo for 8 weeks. The primary endpoint was corticosteroid-free clinical remission with endoscopic remission or response at week eight. After week eight, FMT responders were randomised again to either continue or withdraw FMT for an additional 48 weeks.

The results show that eight out of 15 patients in the FMT group (53%) achieved the primary outcome, as did three out of 20 patients in the placebo group (15%), with a difference of 38.3% between groups.

Adverse events occurred in 10 patients in the FMT group and 17 in the placebo group, and were mainly mild and self-limiting gastrointestinal complaints. Of the 10 patients in the FTM group, four were randomised to continue treatment and maintained remission at week 56.

Oral FMT could be a promising and feasible treatment option for patients with ulcerative colitis, the authors concluded.

This article originally appeared on Univadis, part of the Medscape Professional Network.


Lead image: SciePro/

Image 1: SciePro/